Capricor Therapeutics, Inc.

NasdaqCM:CAPR Stock Report

Market Cap: US$176.6m

Capricor Therapeutics Dividend

Dividend criteria checks 0/6

Capricor Therapeutics does not have a record of paying a dividend.

Key information

n/a

Dividend yield

n/a

Payout ratio

Industry average yield2.9%
Next dividend pay daten/a
Ex dividend daten/a
Dividend per sharen/a
Earnings per share-US$0.76
Dividend yield forecast in 3Yn/a

Recent dividend updates

No updates

Recent updates

Here's Why Capricor Therapeutics, Inc.'s (NASDAQ:CAPR) CEO May Have Their Pay Bumped Up

May 08
Here's Why Capricor Therapeutics, Inc.'s (NASDAQ:CAPR) CEO May Have Their Pay Bumped Up

Benign Growth For Capricor Therapeutics, Inc. (NASDAQ:CAPR) Underpins Stock's 26% Plummet

Apr 19
Benign Growth For Capricor Therapeutics, Inc. (NASDAQ:CAPR) Underpins Stock's 26% Plummet

We're Not Very Worried About Capricor Therapeutics' (NASDAQ:CAPR) Cash Burn Rate

Apr 16
We're Not Very Worried About Capricor Therapeutics' (NASDAQ:CAPR) Cash Burn Rate

Capricor Therapeutics, Inc.'s (NASDAQ:CAPR) 25% Dip In Price Shows Sentiment Is Matching Revenues

Feb 03
Capricor Therapeutics, Inc.'s (NASDAQ:CAPR) 25% Dip In Price Shows Sentiment Is Matching Revenues

Is Capricor Therapeutics (NASDAQ:CAPR) In A Good Position To Invest In Growth?

Dec 13
Is Capricor Therapeutics (NASDAQ:CAPR) In A Good Position To Invest In Growth?

Here's Why We're Not Too Worried About Capricor Therapeutics' (NASDAQ:CAPR) Cash Burn Situation

Aug 13
Here's Why We're Not Too Worried About Capricor Therapeutics' (NASDAQ:CAPR) Cash Burn Situation

A Look At The Fair Value Of Capricor Therapeutics, Inc. (NASDAQ:CAPR)

Nov 03
A Look At The Fair Value Of Capricor Therapeutics, Inc. (NASDAQ:CAPR)

Capricor Therapeutics GAAP EPS of -$0.29 misses by $0.03

Aug 10

Companies Like Capricor Therapeutics (NASDAQ:CAPR) Are In A Position To Invest In Growth

Feb 01
Companies Like Capricor Therapeutics (NASDAQ:CAPR) Are In A Position To Invest In Growth

We Think Capricor Therapeutics (NASDAQ:CAPR) Can Afford To Drive Business Growth

Oct 14
We Think Capricor Therapeutics (NASDAQ:CAPR) Can Afford To Drive Business Growth

Capricor Therapeutics Announces Another 'Final' 12-Month P2 Duchenne Muscular Dystrophy Trial Result

Sep 25

Capricor Therapeutics slumps 9% on $75M stock offering

Jun 21

Capricor Therapeutics (NASDAQ:CAPR) Is In A Good Position To Deliver On Growth Plans

May 16
Capricor Therapeutics (NASDAQ:CAPR) Is In A Good Position To Deliver On Growth Plans

When Will Capricor Therapeutics, Inc. (NASDAQ:CAPR) Turn A Profit?

Mar 13
When Will Capricor Therapeutics, Inc. (NASDAQ:CAPR) Turn A Profit?

Capricor signs intellectual property license for COVID-19 serology test platform

Feb 01

Capricor and Lonza tie up in DMD development

Jan 12

Stability and Growth of Payments

Fetching dividends data

Stable Dividend: Insufficient data to determine if CAPR's dividends per share have been stable in the past.

Growing Dividend: Insufficient data to determine if CAPR's dividend payments have been increasing.


Dividend Yield vs Market

Capricor Therapeutics Dividend Yield vs Market
How does CAPR dividend yield compare to the market?
SegmentDividend Yield
Company (CAPR)n/a
Market Bottom 25% (US)1.5%
Market Top 25% (US)4.8%
Industry Average (Biotechs)2.9%
Analyst forecast in 3 Years (CAPR)n/a

Notable Dividend: Unable to evaluate CAPR's dividend yield against the bottom 25% of dividend payers, as the company has not reported any recent payouts.

High Dividend: Unable to evaluate CAPR's dividend yield against the top 25% of dividend payers, as the company has not reported any recent payouts.


Earnings Payout to Shareholders

Earnings Coverage: Insufficient data to calculate CAPR's payout ratio to determine if its dividend payments are covered by earnings.


Cash Payout to Shareholders

Cash Flow Coverage: Unable to calculate sustainability of dividends as CAPR has not reported any payouts.


Discover strong dividend paying companies

Simply Wall Street Pty Ltd (ACN 600 056 611), is a Corporate Authorised Representative (Authorised Representative Number: 467183) of Sanlam Private Wealth Pty Ltd (AFSL No. 337927). Any advice contained in this website is general advice only and has been prepared without considering your objectives, financial situation or needs. You should not rely on any advice and/or information contained in this website and before making any investment decision we recommend that you consider whether it is appropriate for your situation and seek appropriate financial, taxation and legal advice. Please read our Financial Services Guide before deciding whether to obtain financial services from us.